BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

132 related articles for article (PubMed ID: 37085030)

  • 1. Pulmonary Hemorrhage in Patients Treated With Thoracic Stereotactic Ablative Radiotherapy and Antiangiogenic Agents.
    Lau BC; Wu YF; No HJ; Ko RB; Devine MD; Das MS; Neal JW; Wakelee HA; Ramchandran K; Gensheimer MF; Diehn M; Chin AL; Loo BW; Vitzthum LK
    J Thorac Oncol; 2023 Jul; 18(7):922-930. PubMed ID: 37085030
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Comparing the Outcomes of Stereotactic Ablative Radiotherapy and Non-Stereotactic Ablative Radiotherapy Definitive Radiotherapy Approaches to Thoracic Malignancy: A Systematic Review and Meta-Analysis.
    Hegi F; D'Souza M; Azzi M; De Ruysscher D
    Clin Lung Cancer; 2018 May; 19(3):199-212. PubMed ID: 29370978
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Long-term outcomes in patients with central and ultracentral non-small cell lung cancer treated with stereotactic body radiotherapy: single-institution experience.
    Song X; Zhao L; Jiang N; Ding N; Zong D; Zhang N; Wang D; Wen J; He X; Kong C; Zhu X
    Curr Probl Cancer; 2023 Jun; 47(3):100956. PubMed ID: 36966677
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Outcomes of single fraction stereotactic ablative radiotherapy for lung metastases.
    Filippi AR; Badellino S; Guarneri A; Levis M; Botticella A; Mantovani C; Ragona R; Racca P; Buffoni L; Novello S; Ricardi U
    Technol Cancer Res Treat; 2014 Feb; 13(1):37-45. PubMed ID: 23819496
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Stereotactic ablative radiotherapy (SABR) for early-stage central lung tumors: New insights and approaches.
    Tekatli H; Spoelstra FOB; Palacios M; van Sornsen de Koste J; Slotman BJ; Senan S
    Lung Cancer; 2018 Sep; 123():142-148. PubMed ID: 30089586
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Sinoatrial node toxicity after stereotactic ablative radiation therapy to lung tumors.
    Qian Y; Zhu H; Pollom EL; Durkee BY; Chaudhuri AA; Gensheimer MF; Diehn M; Shultz DB; Loo BW
    Pract Radiat Oncol; 2017; 7(6):e525-e529. PubMed ID: 28669706
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Safety and Effectiveness of Stereotactic Ablative Radiotherapy for Ultra-Central Lung Lesions: A Systematic Review.
    Chen H; Laba JM; Zayed S; Boldt RG; Palma DA; Louie AV
    J Thorac Oncol; 2019 Aug; 14(8):1332-1342. PubMed ID: 31075543
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Long-term toxicity and survival outcomes after stereotactic ablative radiotherapy for patients with centrally located thoracic tumors.
    Atalar B; Mustafayev TZ; Sio TT; Sahin B; Gungor G; Aydın G; Yapici B; Ozyar E
    Radiol Oncol; 2020 Jun; 54(4):480-487. PubMed ID: 32589607
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Stereotactic ablative radiotherapy versus standard radiotherapy in stage 1 non-small-cell lung cancer (TROG 09.02 CHISEL): a phase 3, open-label, randomised controlled trial.
    Ball D; Mai GT; Vinod S; Babington S; Ruben J; Kron T; Chesson B; Herschtal A; Vanevski M; Rezo A; Elder C; Skala M; Wirth A; Wheeler G; Lim A; Shaw M; Schofield P; Irving L; Solomon B;
    Lancet Oncol; 2019 Apr; 20(4):494-503. PubMed ID: 30770291
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Stereotactic ablative body radiotherapy for lung cancer.
    Franks KN; Jain P; Snee MP
    Clin Oncol (R Coll Radiol); 2015 May; 27(5):280-9. PubMed ID: 25746732
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Stereotactic ablative radiotherapy for operable stage I non-small-cell lung cancer (revised STARS): long-term results of a single-arm, prospective trial with prespecified comparison to surgery.
    Chang JY; Mehran RJ; Feng L; Verma V; Liao Z; Welsh JW; Lin SH; O'Reilly MS; Jeter MD; Balter PA; McRae SE; Berry D; Heymach JV; Roth JA;
    Lancet Oncol; 2021 Oct; 22(10):1448-1457. PubMed ID: 34529930
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Use of Stereotactic Ablative Radiotherapy (SABR) in Non-Small Cell Lung Cancer Measuring More Than 5 cm.
    Tekatli H; van 't Hof S; Nossent EJ; Dahele M; Verbakel WFAR; Slotman BJ; Senan S
    J Thorac Oncol; 2017 Jun; 12(6):974-982. PubMed ID: 28286243
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Outcomes of stereotactic ablative radiotherapy for centrally located early-stage lung cancer.
    Haasbeek CJ; Lagerwaard FJ; Slotman BJ; Senan S
    J Thorac Oncol; 2011 Dec; 6(12):2036-43. PubMed ID: 21892102
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Treatment With Stereotactic Ablative Radiotherapy for Up to 5 Oligometastases in Patients With Cancer: Primary Toxic Effect Results of the Nonrandomized Phase 2 SABR-5 Clinical Trial.
    Olson R; Jiang W; Liu M; Bergman A; Schellenberg D; Mou B; Alexander A; Carolan H; Hsu F; Miller S; Atrchian S; Chan E; Ho C; Mohamed I; Lin A; Berrang T; Bang A; Chng N; Matthews Q; Baker S; Huang V; Mestrovic A; Hyde D; Lund C; Pai H; Valev B; Lefresene S; Tyldesley S
    JAMA Oncol; 2022 Nov; 8(11):1644-1650. PubMed ID: 36173619
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Long-Term Outcomes of Salvage Stereotactic Ablative Radiotherapy for Isolated Lung Recurrence of Non-Small Cell Lung Cancer: A Phase II Clinical Trial.
    Sun B; Brooks ED; Komaki R; Liao Z; Jeter M; McAleer M; Balter PA; Welsh JD; O'Reilly M; Gomez D; Hahn SM; Sepesi B; Rice DC; Heymach JV; Chang JY
    J Thorac Oncol; 2017 Jun; 12(6):983-992. PubMed ID: 28259750
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Is stereotactic ablative radiotherapy equivalent to sublobar resection in high-risk surgical patients with stage I non-small-cell lung cancer?
    Mahmood S; Bilal H; Faivre-Finn C; Shah R
    Interact Cardiovasc Thorac Surg; 2013 Nov; 17(5):845-53. PubMed ID: 23900381
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Treatment outcomes of re-irradiation using stereotactic ablative radiotherapy to lung: a propensity score matching analysis.
    Lee TH; Kim DY; Wu HG; Lee JH; Kim HJ
    Radiat Oncol; 2021 Nov; 16(1):222. PubMed ID: 34794471
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Lung volume reduction after stereotactic ablative radiation therapy of lung tumors: potential application to emphysema.
    Binkley MS; Shrager JB; Leung AN; Popat R; Trakul N; Atwood TF; Chaudhuri A; Maxim PG; Diehn M; Loo BW
    Int J Radiat Oncol Biol Phys; 2014 Sep; 90(1):216-23. PubMed ID: 25015205
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Pulmonary oligometastases: metastasectomy or stereotactic ablative radiotherapy?
    Widder J; Klinkenberg TJ; Ubbels JF; Wiegman EM; Groen HJ; Langendijk JA
    Radiother Oncol; 2013 Jun; 107(3):409-13. PubMed ID: 23773410
    [TBL] [Abstract][Full Text] [Related]  

  • 20. A comparison between accelerated hypofractionation and stereotactic ablative radiotherapy (SABR) for early-stage non-small cell lung cancer (NSCLC): Results of a propensity score-matched analysis.
    Chiang A; Thibault I; Warner A; Rodrigues G; Palma D; Soliman H; Jain S; Poon I; Cheung P
    Radiother Oncol; 2016 Mar; 118(3):478-84. PubMed ID: 26795773
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 7.